INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK;UNIVERSITE DE MONTPELLIER;UNIWERSYTET JAGIELLONSKI;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
发明人:
ZAJDEL, PAWEL,GRYCHOWSKA, KATARZYNA,LAMATY, FREDERIC,COLACINO, EVELINA,BANTREIL, XAVIER,MARTINEZ, JEAN,PAWLOWSKI, MACIEJ,SATALA, GRZEGORZ,BOJARSKI, ANDRZEJ J.,PARTYKA, ANNA,WESOLOWSKA ANNA,KOS, TOMASZ
申请号：
CA2919147
公开号：
CA2919147A1
申请日:
2013.07.25
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.
